Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling and marketing

General and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Progenity

Biora Therapeutics, Inc. engages in the provision of molecular and specialized diagnostic tests to clinicians. Its products include the Preparent Carrier Test, Innatal Prenatal Screen, Riscover Hereditary Cancer Test, and Resura Prenatal Test. The company was founded by Paul W. Hawran and Harry Stylli in 2010 and is headquartered in San Diego, CA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Meten Holding Group Ltd.

Superior Drilling Products

With October only a day away, which penny stocks are you watching? The post Best Penny Stocks to Buy Right Now?

Best Penny Stocks to Buy Right Now? 3 to Watch As October Begins

SAN DIEGO, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, announced today that the company will participate in the 11th annual Partnership Opportunities in Drug Delivery (PODD) Conference, October 28-29, 2021 in Boston.

Progenity to Participate in 11th Annual Partnership Opportunities in Drug Delivery Conference

Alset EHome International

Camber Energy

Are these top penny stocks on your September watchlist? The post Making a List of Penny Stocks to Buy?

Making a List of Penny Stocks to Buy? Check These 3 Out in September

The stock price of Progenity Inc (NASDAQ: PROG) increased by over 27% during intraday trading. This is why it happened.

PROG Stock: Why It Significantly Increased Today

Progenity (PROG) stock is taking off on Tuesday after the company revealed a new patent granted to it for its Preecludia test. The post PROG Stock: The Big Patent News That Has Biotech Penny Stock Progenity Soaring Today appeared first on InvestorPlace.

PROG Stock: The Big Patent News That Has Biotech Penny Stock Progenity Soaring Today

SAN DIEGO, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, announced today that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,112,403 for assessment of preeclampsia using assays for free and dissociated placental growth factor.

Progenity Announces Patent Granted by USPTO for its Preeclampsia Rule-Out Test

SAN DIEGO, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, today announced that the company will participate in two upcoming virtual investor conferences:

Progenity to Participate in Two Upcoming Investor Conferences

SAN DIEGO, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (“Progenity”) (Nasdaq: PROG), an innovative biotechnology company, today announced the closing of its previously announced underwritten public offering of 40,000,000 shares of its common stock and warrants to purchase up to 40,000,000 shares of its common stock, at a public offering price of $1.00 per share and associated warrant.

Progenity Announces Closing of $40 Million Underwritten Public Offering

Investors need to pay close attention to Progenity (PROG) stock based on the movements in the options market lately.

Do Options Traders Know Something About Progenity (PROG) Stock We Don't?

Progenity Inc (NASDAQ: PROG) has priced its previously announced underwritten public offering of 40 million shares and warrants to purchase up to 40 million shares. Each share of common stock is being sold together with one warrant has a combined price of $1.00 per share, raising gross proceeds of $40 million.

Progenity Stock Drops To 52-Week Low On $40M Equity Capital Raise

Today, a number of factors appear to be behind the massive downside move of more than 50% in biotech play PROG stock. The post PROG Stock: 2 Reasons Why Progenity Investors Are Crying as the Penny Stock Plunges appeared first on InvestorPlace.

PROG Stock: 2 Reasons Why Progenity Investors Are Crying as the Penny Stock Plunges

The shares of Progenity, Inc. (Nasdaq: PROG) fell by over 50% pre-market. This is why it happened.

Progenity Shares Fell Over 50% Pre-Market: Why It Happened

SAN DIEGO, Aug. 19, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (“Progenity”) (Nasdaq: PROG), an innovative biotechnology company, today announced the pricing of its previously announced underwritten public offering of 40,000,000 shares of its common stock and warrants to purchase up to 40,000,000 shares of its common stock. Each share of common stock is being sold together with one warrant to purchase one share of common stock at a combined public offering price of $1.00 per share of common stock and accompanying warrant, less underwriting discounts and commissions. The warrants have an exercise price of $1.00 per share, are exercisable immediately, and will expire five years following the date of issuance. Progenity expects to receive gross proceeds from the underwritten public offering of approximately $40 million, before deducting underwriting discounts and commissions and other offering expenses.

Progenity Announces Pricing of $40 Million Public Offering of Common Stock and Warrants

SAN DIEGO, Aug. 19, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (“Progenity”) (Nasdaq: PROG), an innovative biotechnology company, announced today that it intends to offer and sell, subject to market and other conditions, shares of its common stock and warrants to purchase shares of its common stock in an underwritten public offering. The proposed public offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.

Progenity Announces Proposed Underwritten Public Offering of Common Stock and Warrants

Progenity, Inc. (PROG) CEO Harry Stylli on Q2 2021 Results - Earnings Call Transcript

Progenity, Inc. (PROG) delivered earnings and revenue surprises of 18.75% and -97.68%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Progenity, Inc. (PROG) Reports Q2 Loss, Misses Revenue Estimates

Announced successful completion of the validation study PRO-104 for the Preecludia™  rule out test for preeclampsia and achievement of the primary endpoint of the study protocol

Progenity Provides Corporate Update and Reports Second Quarter 2021 Financial Results

Progenity, Inc. (PROG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Progenity, Inc. (PROG) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

The company's Preecludia™ test performed strongly in a broad, intended-use population The company's Preecludia™ test performed strongly in a broad, intended-use population

Progenity Announces Successful Completion of Clinical Validation Study and Achievement of the Primary Endpoint for its Preeclampsia Rule-Out Test

SAN DIEGO, June 30, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, announced the appointment of Surbhi Sarna to its board of directors effective July 1, 2021. Ms. Surbhi's medical device experience and her focus on development of strategic partnerships will prove valuable as the company advances its innovation pipeline.

Progenity Announces Appointment of Surbhi Sarna to its Board of Directors

Ambev

ENGlobal

Invesco Mortgage Capital

Kelso Technologies

Ocugen, Inc.

Uranium Energy

With July only a week away, which penny stocks are investors watching right now? The post Hot Penny Stocks to Buy in 2021?

Hot Penny Stocks to Buy in 2021? Check These 7 Out Right Now

SAN DIEGO, June 17, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, today announced the formation of its Inflammatory Bowel Disease Clinical Advisory Board. The advisory board includes respected researchers and clinicians who are thought leaders in the research and treatment of inflammatory bowel disease (IBD).

Progenity Establishes Inflammatory Bowel Disease Clinical Advisory Board

Implied Volatility Surging for Progenity (PROG) Stock Options

SAN DIEGO, June 15, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, today announced that Harry Stylli, PhD, CEO, chairman of the board, and co-founder of Progenity, will participate in a fireside chat at the virtual Raymond James 2021 Human Health Innovation Conference at 10:40 a.m. ET / 7:40 a.m. PT on Tuesday, June 22, 2021.

Progenity to Participate in the Raymond James 2021 Human Health Innovation Conference

Transocean

Looking for penny stocks under $5? Check these 3 out The post Hot Penny Stocks to Buy Under $5?

News for Progenity Stock (PROG)